{"filings":[{"id":759796,"accession_number":"0001104659-26-068604","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-06-01T12:10:58+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 55% (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 wks follow-up; 52.9% in ovarian, 66.7% in USC.","TEAEs leading to dose discontinuation in 3 patients (Gr2 ILD, Gr3 fungal pneumonia, Gr4 thrombocytopenia); no primary prophylaxis for hematologic toxicities used.","Patients heavily pretreated: median 5 prior systemic regimens (range 1-12); 78% ovarian cancer.","Cash, cash equivalents and marketable securities expected to fund operations into Q1 2027.","Virtual KOL event scheduled for June 2, 2026 at 8 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94498,"accession_number":"0001104659-26-057171","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q1 net loss $9.8M; cash $29.7M; SIM0505 Fast Track & ASCO data in June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.7M at March 31, 2026, down $12.1M from year-end; runway into H1 2027 through proof-of-concept for SIM0505.","Net loss $9.8M (vs $11.0M YoY); R&D $6.8M, G&A $3.3M, both down vs prior year.","SIM0505 (CDH6 ADC) granted FDA Fast Track for platinum-resistant ovarian cancer; Phase 1 dose optimization initiated May 2026.","Initial Phase 1 dose escalation data for SIM0505 to be presented at ASCO 2026 on June 1, 2026, including US and China patients.","LNCB74 (B7-H4 ADC) Phase 1 dose escalation enrollment ongoing; trial progress update expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106925,"accession_number":"0001104659-26-024121","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.","Net loss for FY2025: $55.8M, roughly flat vs $55.7M in FY2024; R&D expenses rose to $44.9M.","SIM0505 (CDH6 ADC) Phase 1 dose escalation data and dose optimization start in ovarian cancer both expected Q2 2026.","LNCB74 (B7-H4 ADC) Phase 1 dose escalation update anticipated in second half of 2026.","Company expects current resources to fund operations into first half of 2027 through proof-of-concept for SIM0505."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106924,"accession_number":"0001104659-26-006021","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure reports $41.8M cash; SIM0505 data Q2 2026, LNCB74 delayed to H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and marketable securities of $41.8M as of Dec 31, 2025; runway into H1 2027.","SIM0505 (CDH6 ADC) Phase 1 dose escalation data expected Q2 2026; dose optimization starts H1 2026.","LNCB74 (B7-H4 ADC) higher dose cohorts underway; proof-of-concept data delayed from H1 to H2 2026.","Both programs target gynecological cancers; LNCB74 now includes adenoid cystic carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123251,"accession_number":"0001104659-25-123305","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure enters ATM agreement for up to $14.5M common stock offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows sale of up to $14.5M of common stock at market prices, effective December 19, 2025.","Agent H.C. Wainwright receives 3.0% compensation on gross proceeds from shares sold.","Net proceeds to fund general corporate purposes, including preclinical studies and clinical trials.","Sales may be made on Nasdaq or in negotiated transactions; no minimum price or volume commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123250,"accession_number":"0001104659-25-112975","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure closes $21.5M PIPE led by Ikarian, Squadron; extends cash runway into H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$21.5M from PIPE closed Nov 14, 2025; 708,428 shares at $8.52 and 1,815,049 pre-funded warrants at $8.519.","Lead investors: Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, Exome Asset Management; H.C. Wainwright placement agent.","Cash runway extended into H1 2027, beyond planned H1 2026 POC data readouts for SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC).","Registration rights agreement entered to file resale registration statement with SEC for the sold securities.","Management believes existing cash, equivalents, and marketable securities sufficient to fund operations into first half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123249,"accession_number":"0001104659-25-107008","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.","Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.","SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.","LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.","$12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn."],"consensus_eps_estimate":null,"consensus_eps_actual":-18.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139930,"accession_number":"0001558370-25-011752","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NextCure CSO resigns effective Sept 1, 2025; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Solomon Langermann, Ph.D., resigned as Chief Scientific Officer, effective September 1, 2025.","Resignation was not due to any disagreement with the Company or its operations.","No successor has been announced at this time.","Board and Company thanked Dr. Langermann for his contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139929,"accession_number":"0001558370-25-010774","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.","First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.","LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.","Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.","Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139928,"accession_number":"0001558370-25-009214","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"NextCure effects 1:12 reverse stock split effective July 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1:12, effective 12:01 a.m. ET on July 14, 2025.","Stockholders approved split ratio range of 1:5 to 1:15; Board chose 1:12.","No fractional shares; cash payment for fractional shares based on closing price prior to effective date.","Authorized shares remain 100 million; all outstanding options, warrants, and equity plans adjusted proportionally.","Common stock continues trading under ticker NXTC on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139927,"accession_number":"0001558370-25-009163","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NextCure approves 1-for-12 reverse stock split effective July 14, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1:12 reverse stock split; effective July 14, 2025 with split-adjusted trading at market open.","Every 12 shares convert into 1 share; fractional shares paid in cash based on prior day's closing price.","Outstanding equity awards, incentive plans, and exercise prices adjusted proportionally to the split.","No change to common stock par value; trading symbol remains NXTC on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157531,"accession_number":"0001558370-25-008789","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NextCure stockholders elect directors, ratify auditor, approve reverse stock split at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class III directors David Kabakoff, Michael Richman, and Stephen W. Webster for three-year terms expiring 2028.","Ratified Ernst & Young LLP as independent auditor for fiscal year 2025 with 18.8M for, 1.4M against.","Approved say-on-pay (11.3M for, 0.4M against) and frequency vote of every year (11.7M for).","Approved amendment to certificate of incorporation to authorize reverse stock split when determined by the Board (18.2M for, 2.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157530,"accession_number":"0001558370-25-008633","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"NextCure licenses ADC SIM0505 from Simcere Zaiming in deal worth up to $745M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash $12M + $5M payable upon financing or by Dec 31, 2025; milestones up to $745M plus tiered royalties up to double digits.","Private placement: Simcere affiliate buys 4,063,633 shares at $0.492/share for $2M; registration rights granted.","SIM0505 (CDH6-targeting ADC) in Phase 1 in China; US Phase 1 expected Q3 2025 with initial data in H1 2026.","NextCure also obtains non-exclusive license to Simcere's linker/payload for a novel target ADC; Simcere retains Greater China rights.","Cash runway into mid-2026 based on current resources; company expects to exhaust sooner if assumptions prove incorrect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157529,"accession_number":"0001558370-25-006106","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.","Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.","LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.","Proof-of-concept data readout for LNCB74 planned in first half of 2026.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157528,"accession_number":"0001558370-25-004651","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure updates corporate presentation on LNCB74 trial; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation for LNCB74, a clinical-stage candidate, furnished on April 10, 2025.","Company engaging with investment community referencing updated materials.","No new clinical data, enrollment figures, or milestones provided in the filing or exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175905,"accession_number":"0001558370-25-002396","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports FY2024 net loss of $55.7M; cash $68.6M, LNCB74 Phase 1 advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.7M in FY2024 improved from $62.7M in FY2023; R&D expenses $41.5M, G&A $15.7M, both down YoY.","Cash, equivalents, and marketable securities $68.6M at Dec 31, 2024 (vs $108.3M); expected to fund operations into H2 2026.","LNCB74 (B7-H4 ADC) Phase 1: completed cohort 1 in Feb 2025, currently dosing cohort 2; backfill cohorts planned H2 2025.","Preclinical non-oncology programs (NC181 for Alzheimer's, NC605 for osteogenesis imperfecta) seeking partnerships.","Potential IND filings for NC181 and NC605 within 12-18 months if partner or third-party funding secured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175904,"accession_number":"0001558370-25-000603","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NextCure receives Nasdaq bid price deficiency notice; has until July 30, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified NextCure that its closing bid price was below $1.00 for 30 consecutive business days.","Company has 180-day grace period ending July 30, 2025 to meet the $1.00 minimum bid for 10 consecutive days.","If not compliant, NextCure may seek an additional 180-day extension if it meets other listing standards.","The company is evaluating options including a reverse stock split; delisting risk remains.","No immediate effect on trading; stock continues trading on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175903,"accession_number":"0001558370-25-000099","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.","LNCB74 is being developed as a therapeutic for treating multiple cancers.","FDA cleared the IND for LNCB74 in December 2024.","LNCB74 is developed in partnership with LigaChem Biosciences.","Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192813,"accession_number":"0001558370-24-016108","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).","Phase 1 trial will evaluate LNCB74 for multiple cancers.","LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.","NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.","IND acceptance allows NextCure to proceed with clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192812,"accession_number":"0001558370-24-016026","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure files IND for product candidate LNCB74","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Investigational New Drug application with FDA for LNCB74.","Updated corporate presentation to reflect the IND filing.","Company engaging with investment community starting December 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192811,"accession_number":"0001558370-24-015060","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NextCure furnishes November 2024 corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company hosting calls with investment community beginning Nov. 8, 2024, referencing the presentation.","Presentation furnished as Exhibit 99.1 under Regulation FD; not deemed filed.","No financial or clinical updates extracted from the exhibit text provided.","Stock ticker NXTC, listed on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192810,"accession_number":"0001558370-24-014866","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure Q3 net loss $11.5M, cash $75.3M; plans LNCB74 IND by Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.5M for Q3 2024, vs $14.3M in Q3 2023; R&D expense down to $8.8M.","Cash, cash equivalents, and marketable securities $75.3M as of Sep 30, 2024; expected runway into H2 2026.","LNCB74 (B7-H4 ADC) IND planned by Q4 2024; preclinical data at SITC in November.","NC410 combo trial concluding, seeking partner; ovarian ICI-naïve response rate 25% (5/20) and CRC MSS 8.3% (3/36) PRs at 100 mg.","Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis) also seeking partner or financing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209239,"accession_number":"0001558370-24-010598","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).","Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.","LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.","NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.","NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227174,"accession_number":"0001558370-24-009401","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NextCure shareholders reject officer exculpation amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal to amend charter to exculpate officers failed: 10,638,433 for, 2,863,486 against, 11,212 abstain.","Elaine V. Jones and Ellen G. Feigal elected as Class II directors with 11.8M and 12.9M votes for, respectively.","Ernst & Young LLP ratified as independent auditor for FY2024: 21,818,499 for, 98,189 against.","Broker non-votes of 8,403,929 on director election and exculpation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227173,"accession_number":"0001558370-24-009282","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NextCure CMO Han Myint retires July 1; becomes consultant through 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Han Myint retires as CMO effective July 1, 2024; will provide consulting services starting July 2, 2024 on clinical trials and join Scientific Advisory Board.","The Company will provide continued salary and healthcare benefits through March 31, 2025.","Equity awards continue to vest during the consulting term; exercisability period extended to 90 days after term expiration.","Consulting agreement initial term through July 2, 2025, auto-renewing annually unless terminated by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227172,"accession_number":"0001558370-24-006543","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.","Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.","Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.","LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246061,"accession_number":"0001558370-24-003671","cik":1661059,"company_name":"NextCure, Inc.","ticker":"NXTC","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NextCure reports FY2023 net loss $62.7M; workforce cut 37% to extend cash runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $108.3M at Dec 31, 2023 (down from $159.9M); net loss $62.7M vs $74.7M prior year.","Workforce reduction ~37%; internal GMP manufacturing paused; one-time restructuring charges ~$0.8M expected in Q2 2024.","NC410 combo: 42.8% ORR (3 PRs in 7 evaluable ovarian patients); CRC cohort 10.5% ORR (2/19), median PFS 8.1 months.","LNCB74 (B7-H4 ADC) IND planned by year-end 2024; cost-sharing with LegoChem Biosciences.","Cash runway now expected into second half of 2026 following restructuring and cost reductions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22124087.273476113,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}